TEL: (019467) 74716
Compensation Scheme Executive Secretariat, Sellafield Limited
Sellafield, Seascale, Cumbria CA20 1PG

MOD/AWE

The MOD / AWE CSMB Annual Progress Statement to Council 2019

This report from the Ministry of Defence (MOD) and Atomic Weapons Establishment (AWE) CSMB to the Compensation Scheme Council provides a brief description of MOD and AWE’s involvement within the Scheme. This includes the key issues considered by the CSMB during FY 2018-2019 and an update on the number of cases being dealt with under the Scheme.

Organisation

Union Participation - The majority of claimants who are union members are members of Prospect, Unite or GMB.

MOD Operating sites - The MOD operates a number of MOD nuclear sites and submarines. The MOD also provides medical services (including medical X-ray), carries out a wide range of industrial radiography, operates RADAR equipment and uses radioactive materials to support operational requirements. MOD employees may also be exposed to environmental radiation sources in the course of their employment.

AWE provides the nuclear weapon deterrent and national nuclear security activities on behalf of MOD.

History within the Scheme and Working Arrangements

The MOD/AWE CSMB has now been operating for twenty four years. It met once between the 1 April 2018 and 1 April 2019 and sent employer representatives to the technical working party meeting held during this period.

Case Work

Since the formation of the board, there has been a total of 486 MOD/AWE cases received which have been eligible for detailed consideration by the Scheme. Twenty of these have qualified for compensation payments and have been settled, two are ongoing, one of which is close to resolution.

Since the previous report, 9 new enquiries have been received, 2 of which have been completed/closed out and 1 which was ineligible (ineligible disease).

Complex issues and reliance on supply of information from external data providers including difficulties in obtaining certificates of diagnosis are still delaying the majority of cases supported by DSTL/INM.

AWE has had no significant delays in collating data for external and internal dosimetry.  However, cases have been closed outside timescales due to delays in obtaining personnel information and certificates of diagnosis.

Contribution to Scheme

Dstl has not significantly contributed to the scheme in the last financial year other than ensuring cases are processed within the appropriate timeframes. Similarly, AWE has not made any significant changes to their protocols during this period.  AWE continue to meet with their unions prior to the MOD/AWE Board.